Moderna expands its footprint; EntreMed plots a name change;

@FierceBiotech: This week's Chutes & Ladders: CEO John Johnson jumps ship as Dendreon sinks lower. Report | Follow @FierceBiotech

@JohnCFierce: I have no idea if Porges will be successful, but it's damn good fun to report on it. | Follow @JohnCFierce

@DamianFierce: Break up Amgen Pt. II: Analyst says its moonshot R&D approach is bad for business. Story | Follow @DamianFierce

@EmilyMFierce: Think tank: $4.5B investment in BRAIN Initiative too modest. More | Follow @EmilyMFierce

> Moderna Therapeutics has doubled its capacity, settling in to a 50,000-square-foot space in Cambridge, MA's Kendall Square. More

>  Maryland biotech EntreMed ($ENMD) is planning to change its name to CASI Pharmaceuticals and switch its Nasdaq symbol to "CASI." News

> NIH is asking for $4.5 billion to fund its 10-year BRAIN Initiative, a figure one think tank says is far too low. Story

Medical Device News

@FierceMedDev: Chrono Therapeutics snares $32M in Series A money for wearable smoking cessation device. More | Follow @FierceMedDev

@StacyALawrence: Mobile medical app brings laboratory testing to the home. Story | Follow @StacyALawrence

@MichaelGFierce: UCSB study: New silver nanoparticles dissolve if they don't hit their mark. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: C.R. Bard wins unanimous FDA panel vote for drug-eluting balloon catheter. Article | Follow @EmilyWFierce

> World's tiniest blood glucose monitor launches for iPhone, Android. More

> Medtronic scores FDA approval for TAVR in high-risk patients. Story

> With stroke of genius from a plunger, new med device cuts costs for healing wounds. Item

Pharma News

@FiercePharma: Vivus hits Actavis with Qsymia patent-infringement lawsuit. Story | Follow @FiercePharma

@TracyStaton: Trending at FiercePharmaMarketing: Do reps push drugs off-label? Study says yes. Does it work? Also yes. More | Follow @TracyStaton

@EricPFierce: Biolyse is back in production with paclitaxel after a re-inspection by Health Canada cleared its plant. News | Follow @EricPFierce

@CarlyHFierce: With patent extension up for grabs, Shire agrees to test Vyvanse in preschoolers. More | Follow @CarlyHFierce

@JustinHFierce: New Pet Pace med device monitors temp and vitals, marketed for owners and vets like an e-dog-whisperer. Article | Follow @JustinHFierce

> U.K. price watchdog weighs in on BMS melanoma blockbuster Yervoy. More

> Roche and Cipla are ordered to mediate in a new twist on Indian IP fights. Story

> Chinese companies ready to pump out generic Viagra as patent expires. Item

Suggested Articles

A new, late-phase analysis of cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year and a half.

The data were highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.